ATP - Solution
For research use only.
Please centrifuge briefly before opening (volume ≤2 ml).
Description:
Ultrapure ATP supplied as clear aqueous solution.
Shipping: shipped on gel packs
Storage Conditions: store at -20 °C
Shelf Life: 12 months
Molecular Formula: C10H16N5O13P3 (free acid)
Molecular Weight: 507.18 g/mol (free acid)
CAS#: 987-65-5
Purity: ≥ 99 % (HPLC)
Form: clear aqueous solution
Concentration: 100 mM ±2 %
pH: 8.0 ±0.2 (22 °C)
Spectroscopic Properties: λmax 259 nm, ε 15.1 L mmol-1 cm-1 (Tris-HCl pH 7.0)
Applications:
ATP-sensitive calcium channels[1]
V-ATPases (cellular proton pumps)[2]
ATP-coupled chromatin remodelling[3]
ATP-binding cassette transporters[4]
ATP-grasp enzymes[5]
Agonistic ligand, mainly for nucleoside receptor A1
Nucleoside-triphosphates can be converted by different membrane-bound phosphatases into nucleosides acting as nucleoside receptor ligands.
Specific Ligands:
Ligand for purinergic receptors:
P2X1-P2X3[6,7]
P2X1/4[8]
P2X4[7]
P2X7[9,10,11]
P2X1 - P2X7[12]
P2Y1[10,14]
P2Y2[13,14]
P2Y11[14]
Selected References:
[1] Wang et al. (2011) The biological effect of endogenous sulfur dioxide in the cardiovascular system. Eur. J. Pharmacol. 670 (1):1.
[2] Scott et al. (2011) Duelling functions of the V-ATPase. EMBO J. 30 (20):4113.
[3] Erdel et al. (2011) Chromatin remodelling in mammalian cells by ISWI-type complexes--where, when and why? FEBS J. 278 (19):3608.
[4] Gatti et al. (2011) Novel insights into targeting ATP-binding cassette transporters for antitumor therapy. Curr. Med. Chem. 18 (27):4237.
[5] Fawaz et al. (2011) The ATP-grasp enzymes. Bioorg. Chem. 39 (5):185.
[6] Lambertucci et al. (2015) Medicinal chemistry of P2X receptors: Agonists and orthosteic antagonists. Curr. Med. Chem. 22 (7):915.
[7] Ralevic (2015) P2X receptors in the cardiovascular system and their potential as therapeutic targets in disease. Curr. Med. Chem. 22 (7):851.
[8] Harhun et al. (2014) ATP-evoked sustained vasoconstrictions mediated by heteromeric P2X1/4 receptors in cerebral arteries. Stroke 45 (8):2444.
[9] Facci et al. (2014) Toll-like receptors 2, -3 and -4 prime microglia but not astrocytes across central nervous system regions for ATP-dependent interleukin-1β release. Sci. Rep. 4:6824.
[10] Stolz et al. (2015) Homodimeric anoctamin-1, but not homodimeric anoctamin-6, is activated by calcium increases mediated by the P2Y1 and P2X7 receptors. Pflugers Archiv DOI:10.1007/s00424-015-1687-3.
[11] Lord et al. (2014) Pharmacology of a novel central nervous system-penetrant P2X7 antagonist JNJ-42253432. J. Pharmacol. Exp. Ther. 351 (3):628.
[12] Dal Ben et al. (2015) Purinergic P2X receptors: Structural models and analysis of ligand-target interaction. Eur. J. Med. Chem. 89:561.
[13] Xie et al. (2014) The P2Y2 nucleotide receptor mediates the proliferation and migration of human hepatocellular carcinoma cells induced by ATP. J. Biol. Chem. 289 (27):19137.
[14] Kim et al. (2002) Methanocarba modification of uracil and adenine nucleotides: High potency of northern ring conformation at P2Y1, P2Y2, P2Y4 and P2Y11 but not P2Y6 receptors. J. Med. Chem. 45:208.
Volonte et al. (2009) Membrane components and purinergic signalling: the purinome, a complex interplay among ligands, degrading enzymes, receptors and transporters. FEBS J. 276:318.
Yegutkin (2008) Nucleotide and nucleoside converting enzymes: Important modulators of purinergic signalling cascade. Biochim. Biophys. Acta 1783:673.
Hasko et al. (2007) Shaping of monocyte and macrophage function by adenosine receptors. Pharmacol.& Therapeutics 113:264.
Holland et al. (1991) Detection of specific polymerase chain reaction product by utilizing the 5'----3' exonuclease activity of Thermus aquaticus DNA polymerase. Proc. Natl. Acad. Sci. USA 88 (16):7276.
Erlich et al. (1988) Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 29 (239):487.
Williams et al. (1986) Effects of purine nucleotides on the binding of [3H]cyclopentyladenosine to adenosine A1-receptors in rat brain membranes. J. Neurochem. 47 (1):88.
Sanger et al. (1977) DNA sequencing with chain-terminating inhibitors. Proc. Natl. Acad. Sci. USA 74:5463.
| Cat. No. | Amount | Price |
|---|---|---|
| NU-1010 | 1 ml (100 mM) | 52,30 € |
| NU-1010-100ML | 100 ml (100 mM) | Ask for Quotation |
At this point, external content from bioz.com is embedded. When it loads, data (e.g. your IP address) is transmitted to the provider.
Scientific citations for Jena Bioscience nu-1010-sol
79 scientific citations and 13 citation images found by Bioz.
-
Cohesin cofactor dosage sets the rate of loop extrusion, rendering genome folding tunable yet vulnerable to genetic disruption.
Molecular cell, 2026-04-23 · PMID:42030943
Abstract: Genome folding is not static but emerges from dynamic processes that control transcription, replication, recombination, and repair. DNA loop extrusion by cohesin is central to genome organization, yet it remains unclear how cells can tune extrusion kinetics to achieve precise and functional chromosome folding patterns. Here, we show that extrusion rate acts as a tunable biophysical parameter in cells, quantitatively dialed by the respective dosage of the cohesin cofactors NIPBL and PDS5
-
hnRNPUL1 has a dead polynucleotide kinase domain that regulates RNA and protein interactions.
iScience, 2026-03-01 · DOI:10.1016/j.isci.2026.115360
vvity Cat# BLU503H250UC; CAS:
987-65-5 ɣ-32P ATP PerkinElmer/ Revvity Cat# BLU502Z250UC; CAS:987-65-5 α-32P GTP PerkinElmer/ Revvity Cat # BLU506H250UC; CAS: 36051-31-7 m7GP3G (monomethyl cap analog)Jena Bioscience Cat# NU-852S: CAS: 62828-64-2 AMP-PNP Millipore, Sigma Cat# NC1366768; CAS: 25612-73-1 GMP-PNP Millipore, Sigma Cat# G0635; CAS: 148892-91-5 ADP Millipore, Sigma Cat# A-5285; CAS: 7269 -
Mechanisms of HSV-1 helicase-primase inhibition and replication fork complex assembly.
Cell, 2025-12-29 · PMID:41468884
The protein-DNA and inhibitor mixture was incubated with unlabeled 1000 μM
ATP (Jena Bioscience Cat#NU-1010 ), 25 μM GTP, 25 μM UTP, 25 μM CTP (New England Biolabs Cat# N0450L) and 0.5 μM α 32 P-labeled ATP, GTP, UTP, CTP (Perkin Elmer / Revvity, approximately 1 μCi each) in reaction buffer (50 mM Tris-HCl pH 7.5, 10 mM MgCl 2 , 10 mM DTT, 100 μg/ml BSA) at 37 ◦ C for 60 min.
